Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen is well positioned in the market with its Avance Nerve Graft approved as a biologic, strong cash position, and expected 20% revenue growth for FY2026. The company's valuation is supported by a comparable universe analysis, with projected sales per share of $5.31 and net cash of $1.95 per share resulting in a price objective of $50. Despite potential risks such as government regulation risk and competition from larger medical device companies, Axogen has strong growth potential and its differentiated products make it a promising investment opportunity.

Bears say

Axogen is in the early stages of refining its techniques to enter the $754 million TAM in prostate treatment, with a substantive readout expected in 3Q26; their balance sheet is in good shape with $103.6 million in cash and no debt obligations, and management plans to use their positive free cash flow for continued infrastructure investment and opportunistic M&A in nerve repair adjacencies. Their most recent reported total of $16,611 in stock-based compensation has been normalized to $7,236, which will improve the accuracy of estimates for future quarters and adjust operating expenses as well.

AxoGen (AXGN) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 8 analysts, AxoGen (AXGN) has a Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.